Shihong Peng
Overview
Explore the profile of Shihong Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen H, Bian A, Yang L, Yin X, Wang J, Ti C, et al.
Oncogene
. 2024 Jun;
43(27):2132-2134.
PMID: 38839943
No abstract available.
2.
Guo M, Hu P, Xie J, Tang K, Hu S, Sun J, et al.
Genes Dis
. 2024 Apr;
11(4):101164.
PMID: 38560505
Gastric cancer is highly prevalent among digestive tract tumors. Due to the intricate nature of the gastric cancer immune microenvironment, there is currently no effective treatment available for advanced gastric...
3.
Zhang L, Wu M, Guo W, Zhu S, Li S, Lv S, et al.
Biomed Pharmacother
. 2023 Aug;
166:115358.
PMID: 37634473
BCL6 is a transcriptional repressor that regulates multiple genes involved in immune cell differentiation, DNA damage repair, cell cycle, and apoptosis, and is a carcinogenic factor in acute myeloid leukemia...
4.
Peng S, Hu P, Xiao Y, Lu W, Guo D, Hu S, et al.
Clin Cancer Res
. 2021 Nov;
28(3):552-567.
PMID: 34740924
Purpose: Immunotherapies targeting immune checkpoint molecules have shown promising treatment for a subset of cancers; however, many "cold" tumors, such as prostate cancer, remain unresponsive. We aimed to identify a...
5.
Liu H, Peng S, Zhang K, Qin Y, Meng F, He W, et al.
Materials (Basel)
. 2021 Aug;
14(16).
PMID: 34442955
Vanadium-titanium magnetite (VTM) is an important raw material for ironmaking under the situation of increasingly demanding scarce resources. To further improve the metallurgical properties of pellets, and to satisfy the...
6.
Cong X, He Y, Wu H, Wang D, Liu Y, Shao T, et al.
Front Oncol
. 2021 Jun;
11:650919.
PMID: 34150618
Prostate cancer (PCa) is a common aggressive disease worldwide which usually progresses into incurable castration-resistant prostate cancer (CRPC) in most cases after 18-24 months treatment. Androgen receptor (AR) has been...
7.
Chen H, Bian A, Yang L, Yin X, Wang J, Ti C, et al.
Oncogene
. 2021 Jan;
40(8):1440-1457.
PMID: 33420372
Pancreatic cancer is lethal in over 90% of cases since it is resistant to current therapeutic strategies. The key role of STAT3 in promoting pancreatic cancer progression has been proven,...
8.
Lu W, Yu W, He J, Liu W, Yang J, Lin X, et al.
EMBO Mol Med
. 2020 Dec;
13(1):e12798.
PMID: 33283987
Immune checkpoint blockade (ICB) has a limited effect on colorectal cancer, underlining the requirement of co-targeting the complementary mechanisms. Here, we identified prostaglandin E2 (PGE ) receptor 4 (EP4) as...
9.
Zhang W, Shi X, Chen R, Zhu Y, Peng S, Chang Y, et al.
Mol Ther
. 2020 Jun;
28(11):2473-2487.
PMID: 32592689
Long non-coding RNAs (lncRNAs) participate in the development and progression of prostate cancer (PCa). We aimd to identify a novel lncRNA, named lncRNA activated in metastatic PCa (lncAMPC), and investigate...
10.
Hu P, Guo D, Xie J, Chen H, Hu S, Bian A, et al.
Planta Med
. 2020 Mar;
86(7):482-488.
PMID: 32168548
Approximately 40% of compounds with therapeutic potential cannot be successfully developed into drugs owing to their poor pharmaceutical properties, emphasising the need to profile their drug-like properties as early as...